These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 20211435)

  • 1. Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics.
    Khera AV; Rader DJ
    Trends Cardiovasc Med; 2009 Aug; 19(6):195-201. PubMed ID: 20211435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triglyceride-rich lipoproteins and HDL: what do recent trials tell us?
    Stock J
    Atherosclerosis; 2013 Jun; 228(2):329-31. PubMed ID: 23623013
    [No Abstract]   [Full Text] [Related]  

  • 3. CETP-Inhibition and HDL-Cholesterol: A Story of CV Risk or CV Benefit, or Both.
    Nicholls SJ
    Clin Pharmacol Ther; 2018 Aug; 104(2):297-300. PubMed ID: 29901215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis.
    Musunuru K; Kathiresan S
    Circ Res; 2016 Feb; 118(4):579-85. PubMed ID: 26892959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From lipid locus to drug target through human genomics.
    van der Laan SW; Harshfield EL; Hemerich D; Stacey D; Wood AM; Asselbergs FW
    Cardiovasc Res; 2018 Jul; 114(9):1258-1270. PubMed ID: 29800275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 7. Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future.
    Burgess S; Harshfield E
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):124-30. PubMed ID: 26910273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Not Available].
    Jonas H; Annema W; von Eckardstein A; Suter PM
    Praxis (Bern 1994); 2018 Feb; 107(4):215-222. PubMed ID: 29439638
    [No Abstract]   [Full Text] [Related]  

  • 9. Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
    Koopal C; Retterstøl K; Sjouke B; Hovingh GK; Ros E; de Graaf J; Dullaart RP; Bertolini S; Visseren FL
    Atherosclerosis; 2015 May; 240(1):90-7. PubMed ID: 25768710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to address dyslipidemia.
    Parhofer KG
    Curr Opin Lipidol; 2017 Dec; 28(6):452-457. PubMed ID: 28902717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-Lowering Agents.
    Hegele RA; Tsimikas S
    Circ Res; 2019 Feb; 124(3):386-404. PubMed ID: 30702996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dyslipidaemias in 2017: Atherogenic lipoproteins as treatment targets.
    Catapano AL
    Nat Rev Cardiol; 2018 Jan; 15(2):75-76. PubMed ID: 29336436
    [No Abstract]   [Full Text] [Related]  

  • 13. An experimental study on amelioration of dyslipidemia-induced atherosclesis by Clematichinenoside through regulating Peroxisome proliferator-activated receptor-α mediated apolipoprotein A-I, A-II and C-III.
    Liu C; Guo Q; Lu M; Li Y
    Eur J Pharmacol; 2015 Aug; 761():362-74. PubMed ID: 25979856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.
    Tsimikas S
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):157-64. PubMed ID: 26825471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Catabolism of lipoproteins and metabolic syndrome.
    Therond P
    Curr Opin Clin Nutr Metab Care; 2009 Jul; 12(4):366-71. PubMed ID: 19474714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
    Su X; Peng DQ
    Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation and lipid profile in rheumatoid arthritis: bridging an apparent paradox.
    González-Gay MA; González-Juanatey C
    Ann Rheum Dis; 2014 Jul; 73(7):1281-3. PubMed ID: 24907362
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.
    Nordestgaard BG
    Circ Res; 2016 Feb; 118(4):547-63. PubMed ID: 26892957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.